In SURPASS-2 trial, weekly injection of tirzepatide, a GLP-1 and GIP receptor dual agonist, achieved mean weight loss of about 5.5% at week 12 in adults with type 2 diabetes[23]. Here, GCG is linked to type 2 diabetes mellitus.